Moderna, Inc. (NASDAQ:MRNA – Get Free Report) insider Shannon Thyme Klinger sold 563 shares of the stock in a transaction on Friday, December 8th. The stock was sold at an average price of $79.09, for a total transaction of $44,527.67. Following the completion of the transaction, the insider now directly owns 7,912 shares in the company, valued at approximately $625,760.08. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Moderna Trading Up 2.1 %

Shares of NASDAQ:MRNA traded up $1.68 on Monday, hitting $82.00. The company had a trading volume of 3,826,659 shares, compared to its average volume of 3,703,911. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $217.25. The company has a current ratio of 2.46, a quick ratio of 2.35 and a debt-to-equity ratio of 0.04. The firm’s 50-day simple moving average is $82.47 and its two-hundred day simple moving average is $103.99.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($1.39) earnings per share for the quarter, beating the consensus estimate of ($2.01) by $0.62. Moderna had a negative return on equity of 2.14% and a negative net margin of 38.00%. The business had revenue of $1.83 billion for the quarter, compared to analysts’ expectations of $1.37 billion. On average, equities analysts predict that Moderna, Inc. will post -5.97 earnings per share for the current year.

Hedge Funds Weigh In On Moderna

A number of institutional investors have recently added to or reduced their stakes in MRNA. Wade G W & Inc. increased its stake in shares of Moderna by 1.8% in the 1st quarter. Wade G W & Inc. now owns 4,817 shares of the company’s stock worth $740,000 after acquiring an additional 85 shares in the last quarter. Cim Investment Management Inc. lifted its holdings in shares of Moderna by 4.2% during the first quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock valued at $329,000 after purchasing an additional 86 shares during the last quarter. Cetera Advisor Networks LLC lifted its holdings in shares of Moderna by 0.5% during the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock valued at $3,088,000 after purchasing an additional 87 shares during the last quarter. PFG Investments LLC boosted its position in shares of Moderna by 2.1% in the 2nd quarter. PFG Investments LLC now owns 4,383 shares of the company’s stock worth $533,000 after purchasing an additional 91 shares in the last quarter. Finally, Ancora Advisors LLC grew its stake in shares of Moderna by 41.2% in the 1st quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after buying an additional 96 shares during the last quarter. Institutional investors own 64.51% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of research analyst reports. Royal Bank of Canada lowered their price target on Moderna from $180.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, November 3rd. Canaccord Genuity Group started coverage on Moderna in a report on Wednesday, November 29th. They set a “hold” rating and a $82.00 price objective on the stock. TheStreet lowered Moderna from a “c” rating to a “d” rating in a research note on Thursday, November 2nd. Deutsche Bank Aktiengesellschaft downgraded shares of Moderna from a “hold” rating to a “sell” rating and decreased their price target for the stock from $125.00 to $60.00 in a research note on Thursday, November 2nd. Finally, JPMorgan Chase & Co. cut their price objective on shares of Moderna from $93.00 to $90.00 and set a “neutral” rating for the company in a research note on Friday, December 1st. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $133.70.

View Our Latest Report on MRNA

About Moderna (Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Moderna, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Moderna wasn’t on the list.

While Moderna currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Original: MarketBeat News Feed: Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Insider Sells 563 Shares of Stock